What is Leede Financial’s Forecast for CRDL FY2024 Earnings?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Investment analysts at Leede Financial raised their FY2024 EPS estimates for Cardiol Therapeutics in a report issued on Tuesday, November 19th. Leede Financial analyst D. Loe now anticipates that the company will post earnings of ($0.26) per share for the year, up from their previous forecast of ($0.31). The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.36) per share. Leede Financial also issued estimates for Cardiol Therapeutics’ FY2025 earnings at ($0.25) EPS and FY2026 earnings at ($0.24) EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a report on Wednesday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $8.75.

Cardiol Therapeutics Trading Up 2.5 %

NASDAQ:CRDL opened at $1.62 on Thursday. The company has a 50-day moving average price of $1.95 and a 200-day moving average price of $2.08. The stock has a market cap of $132.19 million, a price-to-earnings ratio of -4.04 and a beta of 0.91. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.01. Cardiol Therapeutics has a 12 month low of $0.79 and a 12 month high of $3.12.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CRDL. Jane Street Group LLC purchased a new stake in Cardiol Therapeutics in the third quarter worth about $29,000. Townsquare Capital LLC bought a new stake in shares of Cardiol Therapeutics in the 3rd quarter worth approximately $27,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Cardiol Therapeutics in the 3rd quarter worth approximately $27,000. Foundations Investment Advisors LLC grew its stake in shares of Cardiol Therapeutics by 237.4% in the 3rd quarter. Foundations Investment Advisors LLC now owns 161,950 shares of the company’s stock worth $321,000 after buying an additional 113,950 shares during the last quarter. Finally, Lion Street Advisors LLC increased its position in Cardiol Therapeutics by 7.9% during the 3rd quarter. Lion Street Advisors LLC now owns 273,281 shares of the company’s stock valued at $544,000 after buying an additional 20,000 shares in the last quarter. 12.49% of the stock is owned by hedge funds and other institutional investors.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.